Listed

Sana Biotechnology, Inc.

SANANasdaqCIK 1770121HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$65.4m, Q2 FY2026
Net income−$63.6m, Q2 FY2026
Sana Biotechnology, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m65.6Research and development, Q3 FY2023, three months to 2023-09-30$65.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-08, accession 0000950170-24-123730.Report this figure56.0Research and development, Q4 FY2023, three months to 2023-12-31$56.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-03, accession 0001193125-26-088215. Derived: 12-month figure less the 9-month figure.Report this figure56.4Research and development, Q1 FY2024, three months to 2024-03-31$56.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0000950170-25-066943.Report this figure60.9Research and development, Q2 FY2024, three months to 2024-06-30$60.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-11, accession 0001770121-25-000010.Report this figure53.2Research and development, Q3 FY2024, three months to 2024-09-30$53.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure45.1Research and development, Q4 FY2024, three months to 2024-12-31$45.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-03, accession 0001193125-26-088215. Derived: 12-month figure less the 9-month figure.Report this figure37.2Research and development, Q1 FY2025, three months to 2025-03-31$37.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure29.8Research and development, Q2 FY2025, three months to 2025-06-30$29.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure30.1Research and development, Q3 FY2025, three months to 2025-09-30$30.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure34.9Research and development, Q4 FY2025, three months to 2025-12-31$34.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-03, accession 0001193125-26-088215. Derived: 12-month figure less the 9-month figure.Report this figure28.7Research and development, Q1 FY2026, three months to 2026-03-31$28.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure30.7Research and development, Q2 FY2026, three months to 2026-06-30$30.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure
Operating income$m(2.2)Operating income, Q3 FY2023, three months to 2023-09-30−$2.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-08, accession 0000950170-24-123730.Report this figure(90.6)Operating income, Q4 FY2023, three months to 2023-12-31−$90.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001193125-26-088215. Derived: 12-month figure less the 9-month figure.Report this figure(111)Operating income, Q1 FY2024, three months to 2024-03-31−$110.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0000950170-25-066943.Report this figure(49.4)Operating income, Q2 FY2024, three months to 2024-06-30−$49.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-11, accession 0001770121-25-000010.Report this figure(61.8)Operating income, Q3 FY2024, three months to 2024-09-30−$61.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure(50.9)Operating income, Q4 FY2024, three months to 2024-12-31−$50.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001193125-26-088215. Derived: 12-month figure less the 9-month figure.Report this figure(50.6)Operating income, Q1 FY2025, three months to 2025-03-31−$50.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure(95.0)Operating income, Q2 FY2025, three months to 2025-06-30−$95.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure(43.5)Operating income, Q3 FY2025, three months to 2025-09-30−$43.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure(61.2)Operating income, Q4 FY2025, three months to 2025-12-31−$61.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001193125-26-088215. Derived: 12-month figure less the 9-month figure.Report this figure(48.6)Operating income, Q1 FY2026, three months to 2026-03-31−$48.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure(65.4)Operating income, Q2 FY2026, three months to 2026-06-30−$65.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure
Net income$m1.0Net income, Q3 FY2023, three months to 2023-09-30$984.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-08, accession 0000950170-24-123730.Report this figure(88.1)Net income, Q4 FY2023, three months to 2023-12-31−$88.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001193125-26-088215. Derived: 12-month figure less the 9-month figure.Report this figure(107)Net income, Q1 FY2024, three months to 2024-03-31−$107.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure(50.3)Net income, Q2 FY2024, three months to 2024-06-30−$50.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure(59.9)Net income, Q3 FY2024, three months to 2024-09-30−$59.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure(49.1)Net income, Q4 FY2024, three months to 2024-12-31−$49.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001193125-26-088215. Derived: 12-month figure less the 9-month figure.Report this figure(49.4)Net income, Q1 FY2025, three months to 2025-03-31−$49.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure(93.8)Net income, Q2 FY2025, three months to 2025-06-30−$93.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure(42.2)Net income, Q3 FY2025, three months to 2025-09-30−$42.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure(58.8)Net income, Q4 FY2025, three months to 2025-12-31−$58.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001193125-26-088215. Derived: 12-month figure less the 9-month figure.Report this figure(47.2)Net income, Q1 FY2026, three months to 2026-03-31−$47.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure(63.6)Net income, Q2 FY2026, three months to 2026-06-30−$63.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure
Diluted EPS$ per share0.00Diluted EPS, Q3 FY2023, three months to 2023-09-30$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-08, accession 0000950170-24-123730.Report this figurenot reported(0.49)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0000950170-25-066943.Report this figure(0.21)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-11, accession 0001770121-25-000010.Report this figure(0.25)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figurenot reported(0.21)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure(0.39)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure(0.16)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figurenot reported(0.17)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure(0.22)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure
Basic EPS$ per share0.00Basic EPS, Q3 FY2023, three months to 2023-09-30$0.00 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-08, accession 0000950170-24-123730.Report this figurenot reported(0.49)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.49 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0000950170-25-066943.Report this figure(0.21)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0001770121-25-000010.Report this figure(0.25)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figurenot reported(0.21)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure(0.39)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.39 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure(0.16)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.16 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figurenot reported(0.17)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.17 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure(0.22)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure

Balance sheet

Cash and equivalents$57.1m, Q2 FY2026
Shareholders' equity$154.6m, Q2 FY2026
Sana Biotechnology, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m168Cash and equivalents, Q3 FY2023, at 2023-09-30$168.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-08, accession 0000950170-23-061171.Report this figure134Cash and equivalents, FY2023, at 2023-12-31$133.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-03, accession 0001193125-26-088215.Report this figure177Cash and equivalents, Q1 FY2024, at 2024-03-31$177.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-08, accession 0000950170-24-055727.Report this figure135Cash and equivalents, Q2 FY2024, at 2024-06-30$135.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0000950170-24-094052.Report this figure127Cash and equivalents, Q3 FY2024, at 2024-09-30$127.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-08, accession 0000950170-24-123730.Report this figure128Cash and equivalents, FY2024, at 2024-12-31$127.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-03, accession 0001193125-26-088215.Report this figure96.1Cash and equivalents, Q1 FY2025, at 2025-03-31$96.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0000950170-25-066943.Report this figure71.3Cash and equivalents, Q2 FY2025, at 2025-06-30$71.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0001770121-25-000010.Report this figure103Cash and equivalents, Q3 FY2025, at 2025-09-30$103.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure71.9Cash and equivalents, FY2025, at 2025-12-31$71.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure83.8Cash and equivalents, Q1 FY2026, at 2026-03-31$83.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure57.1Cash and equivalents, Q2 FY2026, at 2026-06-30$57.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure
Current assets$m280Current assets, Q3 FY2023, at 2023-09-30$279.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-08, accession 0000950170-23-061171.Report this figure214Current assets, FY2023, at 2023-12-31$213.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-17, accession 0000950170-25-040254.Report this figure321Current assets, Q1 FY2024, at 2024-03-31$321.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-08, accession 0000950170-24-055727.Report this figure263Current assets, Q2 FY2024, at 2024-06-30$263.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-094052.Report this figure210Current assets, Q3 FY2024, at 2024-09-30$210.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-08, accession 0000950170-24-123730.Report this figure161Current assets, FY2024, at 2024-12-31$160.8m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-03, accession 0001193125-26-088215.Report this figure113Current assets, Q1 FY2025, at 2025-03-31$112.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0000950170-25-066943.Report this figure82.5Current assets, Q2 FY2025, at 2025-06-30$82.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-11, accession 0001770121-25-000010.Report this figure162Current assets, Q3 FY2025, at 2025-09-30$161.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure149Current assets, FY2025, at 2025-12-31$148.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure112Current assets, Q1 FY2026, at 2026-03-31$111.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure171Current assets, Q2 FY2026, at 2026-06-30$170.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure
Total assets$m631Total assets, Q3 FY2023, at 2023-09-30$631.4m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-08, accession 0000950170-23-061171.Report this figure565Total assets, FY2023, at 2023-12-31$565.3m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-17, accession 0000950170-25-040254.Report this figure681Total assets, Q1 FY2024, at 2024-03-31$681.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-08, accession 0000950170-24-055727.Report this figure619Total assets, Q2 FY2024, at 2024-06-30$618.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0000950170-24-094052.Report this figure559Total assets, Q3 FY2024, at 2024-09-30$559.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-08, accession 0000950170-24-123730.Report this figure501Total assets, FY2024, at 2024-12-31$501.0m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-03, accession 0001193125-26-088215.Report this figure445Total assets, Q1 FY2025, at 2025-03-31$445.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0000950170-25-066943.Report this figure362Total assets, Q2 FY2025, at 2025-06-30$361.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-11, accession 0001770121-25-000010.Report this figure435Total assets, Q3 FY2025, at 2025-09-30$435.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure417Total assets, FY2025, at 2025-12-31$416.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure374Total assets, Q1 FY2026, at 2026-03-31$373.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure432Total assets, Q2 FY2026, at 2026-06-30$431.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure
Current liabilities$m66.6Current liabilities, Q3 FY2023, at 2023-09-30$66.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-08, accession 0000950170-23-061171.Report this figure64.5Current liabilities, FY2023, at 2023-12-31$64.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-17, accession 0000950170-25-040254.Report this figure52.9Current liabilities, Q1 FY2024, at 2024-03-31$52.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-08, accession 0000950170-24-055727.Report this figure50.7Current liabilities, Q2 FY2024, at 2024-06-30$50.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-094052.Report this figure47.0Current liabilities, Q3 FY2024, at 2024-09-30$47.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-08, accession 0000950170-24-123730.Report this figure45.4Current liabilities, FY2024, at 2024-12-31$45.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-03, accession 0001193125-26-088215.Report this figure33.2Current liabilities, Q1 FY2025, at 2025-03-31$33.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0000950170-25-066943.Report this figure33.4Current liabilities, Q2 FY2025, at 2025-06-30$33.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-11, accession 0001770121-25-000010.Report this figure35.5Current liabilities, Q3 FY2025, at 2025-09-30$35.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure78.7Current liabilities, FY2025, at 2025-12-31$78.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure86.3Current liabilities, Q1 FY2026, at 2026-03-31$86.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure124Current liabilities, Q2 FY2026, at 2026-06-30$123.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure
Total liabilities$m266Total liabilities, Q3 FY2023, at 2023-09-30$265.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-08, accession 0000950170-23-061171.Report this figure278Total liabilities, FY2023, at 2023-12-31$277.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-17, accession 0000950170-25-040254.Report this figure306Total liabilities, Q1 FY2024, at 2024-03-31$306.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-08, accession 0000950170-24-055727.Report this figure279Total liabilities, Q2 FY2024, at 2024-06-30$279.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0000950170-24-094052.Report this figure267Total liabilities, Q3 FY2024, at 2024-09-30$266.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-08, accession 0000950170-24-123730.Report this figure251Total liabilities, FY2024, at 2024-12-31$250.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-03, accession 0001193125-26-088215.Report this figure236Total liabilities, Q1 FY2025, at 2025-03-31$236.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0000950170-25-066943.Report this figure239Total liabilities, Q2 FY2025, at 2025-06-30$239.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-11, accession 0001770121-25-000010.Report this figure240Total liabilities, Q3 FY2025, at 2025-09-30$240.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure256Total liabilities, FY2025, at 2025-12-31$256.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure254Total liabilities, Q1 FY2026, at 2026-03-31$254.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure277Total liabilities, Q2 FY2026, at 2026-06-30$277.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure
Shareholders' equity$m366Shareholders' equity, Q3 FY2023, at 2023-09-30$365.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-08, accession 0000950170-24-123730.Report this figure288Shareholders' equity, FY2023, at 2023-12-31$287.5m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-03, accession 0001193125-26-088215.Report this figure375Shareholders' equity, Q1 FY2024, at 2024-03-31$375.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure340Shareholders' equity, Q2 FY2024, at 2024-06-30$339.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure292Shareholders' equity, Q3 FY2024, at 2024-09-30$292.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure251Shareholders' equity, FY2024, at 2024-12-31$250.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure209Shareholders' equity, Q1 FY2025, at 2025-03-31$209.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure123Shareholders' equity, Q2 FY2025, at 2025-06-30$122.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure195Shareholders' equity, Q3 FY2025, at 2025-09-30$195.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure161Shareholders' equity, FY2025, at 2025-12-31$160.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure119Shareholders' equity, Q1 FY2026, at 2026-03-31$119.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure155Shareholders' equity, Q2 FY2026, at 2026-06-30$154.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure

Cash flow

Operating cash flow−$32.8m, Q2 FY2026
Capital expenditure$1.6m, Q2 FY2026
Sana Biotechnology, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(63.6)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$63.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-08, accession 0000950170-24-123730. Derived: 9-month figure less the 6-month figure.Report this figure(52.0)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$52.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-03, accession 0001193125-26-088215. Derived: 12-month figure less the 9-month figure.Report this figure(65.6)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$65.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0000950170-25-066943.Report this figure(58.5)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$58.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-11, accession 0001770121-25-000010. Derived: 6-month figure less the 3-month figure.Report this figure(51.8)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$51.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269569. Derived: 9-month figure less the 6-month figure.Report this figure(47.2)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$47.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-03, accession 0001193125-26-088215. Derived: 12-month figure less the 9-month figure.Report this figure(48.7)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$48.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure(33.1)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$33.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-342395. Derived: 6-month figure less the 3-month figure.Report this figure(29.4)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$29.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269569. Derived: 9-month figure less the 6-month figure.Report this figure(32.6)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$32.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-03, accession 0001193125-26-088215. Derived: 12-month figure less the 9-month figure.Report this figure(37.4)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$37.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure(32.8)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$32.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001193125-26-342395. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m2.2Capital expenditure, Q3 FY2023, three months to 2023-09-30$2.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-08, accession 0000950170-24-123730. Derived: 9-month figure less the 6-month figure.Report this figure14.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$14.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-03, accession 0001193125-26-088215. Derived: 12-month figure less the 9-month figure.Report this figure15.8Capital expenditure, Q1 FY2024, three months to 2024-03-31$15.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-08, accession 0000950170-25-066943.Report this figure13.1Capital expenditure, Q2 FY2024, three months to 2024-06-30$13.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-11, accession 0001770121-25-000010. Derived: 6-month figure less the 3-month figure.Report this figure4.1Capital expenditure, Q3 FY2024, three months to 2024-09-30$4.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269569. Derived: 9-month figure less the 6-month figure.Report this figure0.4Capital expenditure, Q4 FY2024, three months to 2024-12-31$436.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-03, accession 0001193125-26-088215. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2025, three months to 2025-03-31$136.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure(0.1)Capital expenditure, Q2 FY2025, three months to 2025-06-30−$112.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001193125-26-342395. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$41.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269569. Derived: 9-month figure less the 6-month figure.Report this figure0.9Capital expenditure, Q4 FY2025, three months to 2025-12-31$873.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-03, accession 0001193125-26-088215. Derived: 12-month figure less the 9-month figure.Report this figure0.3Capital expenditure, Q1 FY2026, three months to 2026-03-31$288.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure1.6Capital expenditure, Q2 FY2026, three months to 2026-06-30$1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001193125-26-342395. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)295.67m, Q2 FY2026
Sana Biotechnology, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares189Diluted shares (weighted), Q3 FY2022, three months to 2022-09-30189,303,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-08, accession 0000950170-23-061171.Report this figure191Diluted shares (weighted), Q1 FY2023, three months to 2023-03-31191,228,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-08, accession 0000950170-24-055727.Report this figure193Diluted shares (weighted), Q2 FY2023, three months to 2023-06-30192,540,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0000950170-24-094052.Report this figure200Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30200,473,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-08, accession 0000950170-24-123730.Report this figure217Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31217,290,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0000950170-25-066943.Report this figure234Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30234,440,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-11, accession 0001770121-25-000010.Report this figure235Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30235,412,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure238Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31237,578,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure238Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30238,409,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure260Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30260,494,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269569.Report this figure277Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31276,856,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001193125-26-216769.Report this figure296Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30295,667,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure

Shares outstanding: 299.36mShares outstanding, period not labelled, at 2026-08-03299,360,637 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-10, accession 0001193125-26-342395.Report this figure at Aug 3, 2026, from the cover of the 10-Q filed Aug 10, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.